GLP-1 Perioperative Management: 2026 ADA Guidelines
The 2025 American Diabetes Association guidelines do not provide specific recommendations for stopping or resuming GLP-1 receptor agonists around surgery. The ADA Standards of Care mention only that SGLT2 inhibitors should be discontinued 3-4 days before surgery and that other oral glucose-lowering agents should be held the morning of surgery, but GLP-1 receptor agonists are conspicuously absent from their perioperative guidance 1.
What the Evidence Actually Shows
Since the ADA has not issued specific GLP-1 perioperative guidance, you must rely on the most recent high-quality anesthesia guidelines, which recommend holding GLP-1 receptor agonists for at least three half-lives before elective surgery 2.
Pre-operative Management Algorithm
For patients taking GLP-1 RAs for weight loss:
- Hold the medication for at least three half-lives before surgery (e.g., 3 weeks for weekly semaglutide, which has a ~7-day half-life) 2
- This is non-negotiable due to aspiration risk outweighing any metabolic benefit
For patients taking GLP-1 RAs for type 2 diabetes:
- Consult endocrinology regarding risks/benefits of holding for three half-lives 2
- Discuss bridging therapy if the drug must be held longer than the next scheduled dose
- The concern here is that prolonged cessation may worsen perioperative glycemic control, but aspiration risk must be weighed against this 2
Why Three Half-Lives?
Three half-lives clears approximately 88% of the drug, though there is no strong evidence that gastric emptying fully normalizes after this period 2. Case reports document aspiration events even when patients stopped GLP-1 RAs 4-6 days before surgery 2, highlighting that shorter cessation periods are inadequate.
High-Risk Situations Requiring Enhanced Precautions
Even if the drug has been held for three half-lives, use full-stomach precautions for patients who:
- Recently started the medication or increased their dose
- Experience nausea, vomiting, or abdominal distention
- Could not hold the medication for three half-lives 2
Risk Mitigation Strategies
- Consider postponing elective surgery if adequate drug clearance time hasn't elapsed
- Implement clear fluid diet for an extended period before standard NPO times 2
- Use point-of-care gastric ultrasound to assess residual gastric contents (proceed if gastric volume <1.5 mL/kg) 2
- Consider prokinetic agents (metoclopramide or erythromycin) preoperatively 2
- Perform rapid-sequence intubation when general anesthesia is required 2
- Consider pre-emptive gastric decompression in very high-risk patients 2
Critical Pitfalls
Standard fasting times are NOT adequate for patients on GLP-1 RAs. Multiple case reports document regurgitation and aspiration despite 10-20 hours of fasting 2. One study found 24.2% of semaglutide patients had residual gastric contents at endoscopy despite discontinuing the drug 10-14 days prior and fasting 12+ hours 2.
Stopping the drug 1 week before surgery is insufficient for long-acting agents. Discontinuation for 7 days did not decrease the prevalence of retained gastric contents in observational studies 2.
When to Resume Post-operatively
The evidence provides no guidance on when to safely resume GLP-1 receptor agonists after surgery. This critical gap means you must use clinical judgment based on:
- Return of normal bowel function
- Tolerance of oral intake without nausea/vomiting
- Resolution of surgical stress and inflammatory response
- Absence of gastroparesis symptoms
A reasonable approach would be to wait until the patient demonstrates normal gastric emptying (tolerating regular diet without symptoms) before restarting, typically several days to a week post-operatively for major surgery.
The Evidence Landscape
The recommendations come from a 2024 narrative review in Anaesthesia 2, not from diabetes society guidelines. The evidence base consists primarily of case reports and small observational studies—there are no randomized trials. The ADA's silence on this issue is notable and problematic given the widespread use of these medications.
Recent data suggests continuation may be reasonable in some asymptomatic patients with enhanced mitigation strategies 3, and one 2026 study found no difference in perioperative glycemic control whether GLP-1 RAs were continued or held 4. However, given the documented aspiration cases and lack of definitive safety data, the conservative three-half-life cessation approach remains the safest recommendation for elective surgery.